

Contributors, xix
International System of Units and Prefixes for Physical
Quantities, xxiii

SECTION 1

1 Atoms, Nuclei and Radioactivity, 2

Elizabeth M. Parvin

Introduction, 2

Atomic Structure, 2

Particles, 2

The Atom and the Nucleus, 3

The Forces, 3

Electron Energy Levels, 4

Band Theory of Solids, 4

Impurity Bands, 5

Particles in Electric and Magnetic Fields, 5

Electric Fields, 5

Magnetic Fields, 5

The Lorentz Equation, 5

Waves, 5

Transverse and Longitudinal Waves, 5

Electromagnetic Radiation, 6

Continuous Spectra and Characteristic Radiation, 7

Radioactive Decay, 8

Stable and Unstable Isotopes, 8

Half-life, 9

Alpha Decay, 9

Beta Decay, 10

Gamma Decay, 10

Electron Capture and Internal Conversion, 11

Radioactive Decay Series, 11

Radionuclides of Medical Interest, 12

References, 12

Further Reading, 12

2 Interactions of Ionising Radiation With Matter, 13

Shakardokht Jafari and Michael Wynne-Jones

Introduction, 13

Charged and Uncharged Particles, 13

Excitation and Ionisation, 13

Electron Interactions, 14

Collisional and Radiative Energy Loss, 14

X-Ray Production, 14

Characteristic X-Rays and Auger Electrons, 16

Stopping Power and Linear Energy Transfer, 16

Range and Path Length, 17

Photon Interactions, 17

The Photoelectric Effect, 17

The Compton Effect, 18

Pair Production, 19

Exponential Attenuation, 19

Attenuation of Photon Spectra, 21

Beam Hardening, 21

Energy Absorption, 22

Photo-Nuclear Interactions, 22

Photon Depth Dose and the Build-Up Effect, 22

Kerma and Absorbed Dose for Radiotherapy

beams, 24

Kerma, 24

Absorbed Dose, 24

Units of Kerma and Dose, 25

Heavy Charged Particle Interactions, 25

Protons, 25

Carbon Ions and Pions, 25

Neutron Interactions, 26

References, 27

Further Reading, 27

3 Radiation Detection and Measurement, 28

Andrew Poynter, Andrzej Kacperek, and John A. Mills

Introduction, 28

Radiation Detection, 28

Gas Amplification Devices, 29

Scintillation Devices, 30

Ideal Air Ionisation Chamber, 30

Proton Beam Detection, 30

Measurement and Standardisation of Dose, 31

Dose Standards, 31

Traceability of Measurement, 31

Standard Calorimeter, 32

The Free Air Chamber, 33

The Proton Beam Dose Standard, 34

Practical Ionisation Chambers, 34

Bragg-Gray Cavity Theory, 34

Dose Determination Based on Calibrated

Instruments, 35

Requirements for Practical Ionisation Chambers, 35

Thimble Ionisation Chamber, 35

Physical Description, 35

Measurement of Dose and Dose Rate, 36

The Parallel-Plate Ionisation Chamber, 37

The Beam Monitor Chamber, 37

Intercomparisons With Secondary Standard

Instruments, 38

Strontium Consistency Check Device, 38

Ionisation Chamber Corrections, 38

Ion Recombination Losses, 38

Correction for Atmospheric Conditions, 38

Chamber Stem Effect, 39

Polarity Effect, 39

Alternative Dose Measurement Systems, 39

Film Dosimetry, 39

Semiconductor Detectors, 40

Thermoluminescent Dosimetry, 42

Chemical and Biochemical Detectors, 43

Fricke Dosimetry, 43

- Ceric Dosimetry*, 44
- Gel Dosimetry*, 44
- Fricke Gels and FXG Gels*, 44
- Polymer Gels*, 44
- Alanine-Electron Paramagnetic Resonance Dosimetry*, 44
- Biological Dosimetry*, 45
- Biological Molecules*, 45
- Genetic Structures*, 45
- Cells and Biological Structures*, 45
- Composite Detectors and Arrays**, 45
 - Linear Detector Arrays*, 45
 - Area Arrays*, 45
 - Volume Detectors Arrays*, 46
- Electronic Portal Dosimetry**, 46
- Alternative Systems for Proton Beams Dose Measurement**, 46
- References**, 47

4 Radiation Protection, 49

Mike Dunn

- Introduction**, 49
- Biological Effects of Radiation**, 49
 - Stochastic Hereditary Effects*, 49
 - Stochastic Somatic Effects*, 50
 - Nonstochastic Somatic Effects*, 50
- Dose Descriptors**, 50
 - Equivalent Dose*, 50
 - Effective Dose*, 50
- Background Radiation**, 52
- Legislative Requirements**, 53
 - The Ionising Radiations Regulations 2017*, 53
 - The Ionising Radiation (Medical Exposure) Regulations 2017*, 56
 - Administration of Radioactive Substances Advisory Committee*, 57
 - Environmental Permitting (England and Wales) Regulations 2016*, 58
 - High Activity Sealed Radioactive Sources and Orphan Sources Regulations 2005*, 58
- Protective Measures**, 58
 - Time*, 58
 - Distance*, 58
 - Barriers*, 58
 - Contamination*, 59
 - Building Materials*, 59
- Monitoring of Radiation Levels**, 60
 - Personal Radiation Dosimeters*, 60
 - Radiation Records*, 61
 - Other Requirements*, 61
- References**, 62

5 Imaging With X-Ray, Magnetic Resonance Imaging and Ultrasound, 64

Andy Rogers, Carl Tiivas, and Sarah Wayte

- Introduction**, 64
- X-Ray Imaging**, 65
 - Overview of X-Ray Imaging Process*, 65

- Production of X-Rays for Imaging*, 65
- Information From Absorption and Scattering*, 66
- Differential Attenuation in the Primary Beam*, 66
- Contrast Media*, 66
- Scatter as Unwanted Background*, 66
- Antiscatter Grid*, 66
- Planar Imaging**, 67
 - Film and Screen Detection*, 67
 - Characteristic Curve*, 68
 - Digital Computed Radiography Using Photostimulable Phosphors*, 68
 - Fluoroscopic Imaging With Image Intensifier Chain*, 68
 - Digital Fluoroscopy and Radiography Using Solid State Detectors*, 69
- Assessment of Image Quality**, 69
 - Magnification Distortion*, 69
 - Resolution, Geometric Unsharpness and Movement*, 69
 - Image Signal and Noise*, 70
 - Dose*, 70
- Tomographic Imaging**, 70
 - Computed Tomographic Reconstruction From Projections*, 70
 - Practical Configurations*, 70
- Dedicated Radiotherapy Systems**, 71
 - Simulator*, 71
 - Computed Tomography Virtual Simulator*, 71
 - Treatment Verification Systems*, 71
- Magnetic Resonance Imaging**, 72
 - Overview of the Magnetic Resonance Imaging Process*, 72
 - Producing a Signal*, 72
 - Returning to Thermal Equilibrium*, 72
 - Imaging Sequences*, 73
 - How Contrast Is Altered in a Magnetic Resonance Image*, 73
 - How Positional Information Is Encoded in the Signal*, 73
- Magnetic Resonance Imaging Scanners**, 75
- Spectroscopy**, 76
- Clinical Applications of Magnetic Resonance Imaging in oncology**, 77
 - Brain Tumours*, 77
 - Body Tumours*, 77
- Ultrasound Imaging**, 77
 - Overview of Ultrasound Imaging Process*, 77
 - Physical Characteristics of Ultrasound Waves*, 77
 - Interactions at Interfaces*, 81
 - Attenuation and Interference*, 81
- Ultrasound Scanners**, 81
 - Production of Ultrasound for Imaging*, 81
 - Derivation of an Ultrasound Image*, 82
 - Brightness Mode Ultrasound Imaging*, 82
 - Linear Array Ultrasound Imaging*, 82
 - Intracavitary and Endoscopic Probes*, 82
 - Harmonic Imaging*, 82
 - Dynamic Imaging*, 82

Contrast and Tissue Characteristic Imaging, 83
Clinical Applications of Ultrasound Imaging, 83
General Imaging, 83
Advantages and Disadvantages, 83
Imaging for Cancer, 84
Clinical Therapeutic Ultrasound, 84
References, 84

6 Imaging With Radionuclides, 85

Paul Hinton

Introduction, 85
Overview of the Radionuclide Imaging Process, 85
Gamma Cameras, 86
Scintillation Gamma Cameras, 86
Solid-State Gamma Cameras, 87
Image Construction, 87
Imaging Techniques, 88
Positron Emission Tomography Scanners, 90
Radiopharmaceuticals, 92
The Radionuclide, 92
Type of Radiation, 92
Physical Half-Life, 92
Specific Activity, 92
Radionuclide Purity, 92
Chemical Properties, 92
The Ideal Radionuclide for Imaging, 92
Mechanisms of Localisation, 92
Production and Quality Control of Radiopharmaceuticals, 93
Clinical Applications, 94
Bone Imaging, 94
Tumour Imaging, 94
Imaging Thyroid Cancer, 96
Cardiac Imaging, 96
Kidney Imaging, 97
Infection Imaging, 98
Sentinel Node Mapping, 99
Positron Emission Tomographic Imaging, 99
Conclusions, 101
References, 101

7 Therapy With Unsealed Radionuclides, 102

Matthew Aldridge and Sofia Michopoulou

Introduction, 102
Iodine-131 in the Treatment of Thyroid Disease, 103
Thyroid Cancer, 103
Benign Thyroid Disease, 105
Palliation of Bone Pain, 105
Molecular Radiotherapy Treatment of Neuroendocrine Tumours, 106
Selective Internal Radiation Therapy, 106
Phosphorus-32 in the Treatment of Refractory Myeloproliferative Disease, 107
Intraarticular and Intracavitary Treatments, 107
Radioimmunotherapy, 107
Radiation Protection, Waste and Regulations, 108
Hospital Requirements, 108
Facilities, 108

Comforters and Carers, 108
Outpatient Therapies, 108
Waste Disposal, 108
References, 109

8 Radiotherapy Devices With Kilovoltage X-Rays and Radioisotopes, 110

Claire Fletcher and John A. Mills

Introduction, 110
Kilovoltage X-Ray Production, 110
X-Rays From Electrons, 110
High-Voltage Circuits, 110
Kilovoltage X-Ray Characteristics, 111
Superficial and Deep Kilovoltage Machines, 111
Tube Stand, 112
Collimation, 112
Skin and Eye Shielding, 112
Control of Output, 113
Calibration of Dose Output, 113
Contact Kilovoltage Machine, 113
Grenz Kilovoltage Machine, 113
Radionuclide Characteristics, 114
Gamma Emitters, 114
Beta Emitters, 114
Brachytherapy and Afterloading Machines, 114
The High Dose Rate Afterloading Machine, 116
Implanted Kilovoltage Machine, 116
Beta-Ray Machine, 117
Gamma-Ray Machine, 117
Radioisotope Source, 118
Beam Collimation, 118
Design of Gamma-Ray Teletherapy Machines, 119
Radiosurgery, 120
Radiation Safety, 120
Commissioning and Quality Control, 120
Conclusion, 120
References, 121

9 Beam Production: Megavoltage Accelerators, 122

Andrzej Kacperek and John A. Mills

Introduction, 122
The Medical Linear Accelerator, 122
Linear Accelerator Layout and Components, 123
X-Ray Beam, 124
Electron Beam, 126
Linear Accelerator Control Systems, 127
Nonstandard Linear Accelerators, 127
Intensity-Modulated Radiotherapy, 127
CyberKnife, 127
Tomotherapy, 127
Volumetric-Modulated Arc Therapy, 127
Stereotactic Ablative Radiotherapy, 127
Flattening Filter-Free Dose Delivery, 128
Patient Alignment for X-Ray and Electron Therapy, 128
Radiation Safety, 131
Acceptance, Commissioning and Quality Control, 131
Treatment Room Design for X-Ray and Electron Protection, 131

- Special Techniques With Linear Accelerators, 132
- The Development of Clinical Proton and Heavier Charged Particle Accelerators, 133
- Particle Accelerator Layout and Components, 134
 - Basic Components of a Cyclotron*, 134
 - Basic Theory of Classic Cyclotron Operation*, 134
 - Ion Source Operation*, 135
 - Characteristics and Limitations for Therapy*, 136
 - Synchrocyclotrons*, 136
 - Azimuthal Vertical Focussing or Isochronous Cyclotrons*, 136
 - Synchrotrons*, 137
- Passive-Scattered Beams and Pencil Beam Scanning Beams, 138
- Gantries, 142
- Types of Proton and Ion Accelerators, 143
- Clinical Proton Therapy Centres, 143
- Clinical Carbon Ion Therapy Centres, 145
- Noncircular Accelerators, 145
- Neutron and Other Beams, 146
 - Fast Neutron Beam Therapy*, 146
 - Boron Neutron Capture Therapy*, 146
 - Proton Boron Capture Therapy*, 146
 - Pion Therapy*, 147
 - Antiproton Therapy Beams*, 147
 - Laser-Induced Proton and Particle Beams*, 147
- Shielding of Proton Therapy Accelerators and Treatment Rooms, 148
- Nanoparticle-Enhanced Therapy, 148
- Future Design, 149
- Record and Verify Systems, 149
- Conclusion, 150
- References, 150

10 Radiation Treatment Planning: Immobilisation, Localisation and Verification Techniques, 152

Andrew Penny and Phil Sharpe

- Introduction, 152
- Patient Immobilisation, 153
 - Thermoplastic Shells*, 153
 - Patient Head Shells*, 154
 - Three Dimensional Printing*, 154
 - Nonshell Fixation Systems*, 154
 - Stereotactic Frames*, 154
 - Body Immobilisation*, 155
- Stereotactic Ablative Body Radiation Therapy, 155
- Surface-Guided Radiotherapy, 155
- Volume Definitions, 155
- Noncomputed Tomography Contouring Devices, 156
- Physical Simulation, 156
- Computed Tomography Simulation, 157
- Virtual Simulation, 157
- A Typical Head and Neck Computed Tomography Simulation Procedure, 159
- Multimodality Images for Planning, 159

- Portal Verification and Image-Guided Treatments, 160
- Portal Imaging*, 160
- Image-Guided Radiotherapy*, 160
- References, 161

11 Radiation Treatment Planning: Beam Models, Principles and Practice, 162

Maria Mania Aspradakis

- Introduction, 162
- Representation of the Patient for Treatment Planning, 163
 - The Planning CT*, 163
 - Patient Immobilisation for Treatment Planning*, 164
 - Motion Management in Treatment Planning*, 164
 - Magnetic Resonance-Based Planning*, 164
- Beam Modelling and Dose Calculations for External MV Photon Beam Treatment Planning, 164
 - Modelling of the Source of Radiation*, 165
 - Modelling of Dose in the Irradiated Medium*, 166
 - Factor-Based Approaches*, 169
 - Conclusion on Model-Based Approaches*, 170
- Dose Per Monitor Unit Formalism: Calculation of Monitor Units, 170
- Treatment Plan Evaluation Tools, 170
 - Isodose Distributions*, 170
 - Beams Eye View*, 171
 - Dose Volume Histograms*, 171
 - Other Tools*, 173
- Treatment Planning Techniques in External MV Photon Beam Radiotherapy, 174
 - Forward and Inverse Planning*, 174
 - Forward Planning With Standard Beam Arrangements*, 174
 - Forward-Planned Intensity-Modulated Radiotherapy*, 180
 - Inverse Planning*, 181
 - Specialised Techniques With MV Photons*, 183
- Electron Therapy, 185
 - Dose Calculations for Electron Beams*, 185
 - Energy and Depth-Dose Characteristics*, 185
 - Penumbra*, 186
 - Standoff and Stand in*, 186
 - Patient Contour Effects*, 186
 - Heterogeneities*, 187
 - Field Matching*, 187
 - Specialised Techniques With Electrons*, 187
- Kilovoltage Photon Therapy, 188
- Differences Between Kilovoltage and Electron Therapy, 188
- Proton and Heavy-Ion Therapy, 188
- Quality Assurance in Treatment Planning, 189
 - Treatment Planning System Commissioning and Performance Testing*, 189
 - Plan-Specific Quality Assurance*, 190
- References, 191

12 Networking, Data, Image Handling and Computing in Radiotherapy, 193

John Sage

- Introduction, 193
 - History, 193
 - Benefits and Hazards of Computerisation, 193
- Networking, 194
 - Link Layer: Physical Infrastructure, 194
 - Network Layer: Addressing, 194
 - Transport Layer: Send and Receive, 195
 - Application Layer: The Program, 195
 - Network Security, 195
 - DICOM, 195
 - DICOM Data Objects, 196
- Radiotherapy Data, 197
 - Data Storage, 197
 - Image Quality, 197
 - Radiotherapy Data Types, 197
 - Data Burden, 198
 - Data Security, 198
- Software Development, 199
- Conclusion, 199
- References, 199

13 Quality Control, 200

John A. Mills and Phil Sharpe

- Introduction, 200
- The Quality Control Required, 200
- Commitment to Quality Control, 201
- Safety, Position and Dose, 201
- Frequency, Tolerances and Failure Trends, 201
- Measurement and Uncertainty, 201
- Null Hypothesis, 202
- Combining Variances and Tolerances, 202
- Setting a Tolerance to Achieve a Performance Level, 202
- Performance Improvement, 202
- Maintenance and Catastrophes, 203
- Long-Term, Short-Term and Immediate Monitoring, 203
 - Immediate Monitoring, 203
 - Long-Term Monitoring, 203
 - Short-Term Monitoring, 203
- The Radiotherapy Process, 203
 - Acquisition, 204
 - Analysis, 204
 - Delivery, 204
- The Need for Patient-Specific Quality Control, 204
- The Radiotherapy Technology, 204
 - Planning Imaging, 204
 - Virtual Simulation, 204
 - Dose Prediction, 205
 - Kilovoltage Machines, 205
 - Afterloading Brachytherapy Machines, 205
 - Megavoltage Machines, 205
 - Patient Positioning, 205
 - Treatment Verification, 205

- Computer Systems and Networking, 205
- Measurement Equipment, 205
- Practical Patient-Specific Quality Control, 206
 - Practical Methods, 206
 - Phantom-Based Measurements, 206
 - Dosimetric Arrays, 206
 - Gamma Index, 206
 - Independent Software Verification, 207
 - Secondary Treatment Planning System, 207
 - Patient-Specific Quality Control Implementation, 207
- Getting Things in Balance, 207
- Quality Control Scheduling for Megavoltage Machines, 207
- Conclusion, 208
- References, 208

14 Quality Management in Radiotherapy, 209

Jill Emmerson, Karen Waite, and Helen Baines

- Introduction: What is Quality?, 209
- History of Quality in Radiotherapy, 210
- Quality Management Systems, 210
 1. Customer Focus, 210
 2. Leadership, 211
 3. Engagement of People, 211
 4. Process Approach, 211
 5. Improvement, 211
 6. Evidence-Based Decision Making, 211
 7. Relationship Management, 211
- The ISO 9000 Standard, 212
 - Clause 4 Context of the Organisation, 212
 - Clause 5 Leadership, 213
 - Clause 6 Planning, 213
 - Clause 7 Support, 213
 - Clause 8 Operation, 213
 - Clause 9 Performance Evaluation, 214
 - Clause 10 Improvement, 214
- The Radiotherapy Process, 214
- An Integrated Approach to Quality and Other Initiatives, 214
 - Quality in the National Health Service, 214
 - Risk Management, 214
 - Clinical Incidents, 216
 - Audit, 217
 - Patient-Focussed Care, 220
- Implementation of New Technology and New Techniques, 221
- Conclusion, 222
- References, 222

SECTION 2

15 Epidemiology of Cancer and Screening, 226

Katie Spencer, David Hole, Paul Symonds, and Eva Morris

- The Cancer Problem, 226
- Cancer in the United States, 226
 - Cancer in Europe, 227

- Epidemiology of Cancer, 227
 - Terminology, 227
- Survival and Cure in Cancer, 227
 - Outcome of Palliative Care, 228
- Epidemiology and The Prevention of Cancer, 228
 - Criteria for Causality, 228
- Aetiology and Screening, 228
 - Lung Cancer, 228
 - Colorectal Cancer, 230
 - Breast, 230
 - Stomach, 232
 - Prostate, 232
 - Cervix, 232
 - Oesophagus, 233
 - Melanoma, 233
 - Head and Neck, 233
 - Lymphoma, 234
 - Leukaemia, 234
- Reducing the Risks of Developing Cancer, 235
 - Reducing Tobacco Smoking, 235
 - Modifying Alcohol Consumption, 236
 - HPV Vaccination, 236
 - Ultraviolet Light, 236
 - Occupational Exposure, 236
 - Diet, 237
 - Ionising Radiation, 237
- Pollution, 237
 - Chemoprevention, 237
- Conclusion, 238
- Further Reading, 238

16 Biological and Pathological Introduction, 239

John R. Goepel and Abhik Mukherjee

- Introduction, 239
- Growth: Proliferation, Differentiation and Apoptosis, 239
 - Growth Disorders, 239
- Neoplasia, 240
 - Benign and Malignant Neoplasms, 240
- Carcinogenesis, 240
 - Initiation, 240
 - Promotion, 240
 - Progression, 240
 - Clinical Cancer, 241
 - Oncogenes and Tumour Suppressor Genes, 241
 - Defective apoptotic mechanisms, 241
 - Blood Vessels, 241
 - Physical Agents, 242
 - Chemicals, 242
 - Viruses and Cancer, 243
 - Immunity and Cancer, 243
 - Injury and Cancer, 243
- Precancerous Lesions, 243
 - Field Change, 244
- Natural History and Spread of Cancer, 244
 - Local Invasion, 244
 - Metastasis, 245
 - Functioning Tumours, 246

- Cause of Death from Cancer, 246
- Staging of Cancers, 246
 - TNM Classification, 246
- Histological Grading: Differentiation, 247
 - Limitations of Grading, 248
- Growth Rate of Cancers, 248
 - Spontaneous Regression of Cancer, 248
- Classification of Neoplasms, 248
 - Undifferentiated Tumours, 249
- Current Advances in Pathology Guiding Patient Management, 251
- Further Reading, 252

17 Molecular, Cellular and Tissue Effects of Radiotherapy, 253

George D.D. Jones and Paul Symonds

- Introduction, 253
- Ionising Radiation, Free Radical Generation, Subcellular Radiogenic Damage, 253
- Recovery, DNA Damage Repair and Damage Signalling, 255
 - Recovery, 255
 - Double-Strand Break Repair and Damage Signalling, 255
 - Epigenetic Radiation Signalling Mechanisms, 255
- Radiation-Induced Cell Killing, 257
 - Tumour Hypoxia, Oxygen Effect and Reoxygenation, 257
 - The Cell Cycle and Sensitivity to Irradiation, 259
 - Patterns of Cell Death After Irradiation, 259
 - Models of Radiation Cell Survival, 260
- Radiation Effects in Normal and Malignant Tissue, 261
 - Acute Responses of Normal Tissue, 261
 - Subacute Reactions of Normal Tissue, 261
 - The Effect of Radiotherapy on Tissues, 261
 - The Tolerance of Normal Tissues, 261
 - Retreatment, 262
 - Response of Tumours to Radiation, 262
 - Overall Treatment Time, 262
 - Modification of Fractionation Patterns, 262
- Other Radiation Modalities, 262
 - Heavy Particle Radiotherapy, 262
 - Drug-Radiotherapy Combinations, 263
- Future Trends (and Pitfalls), 263
 - New Technologies, 263
 - Molecular Studies, 263
- Further Reading, 264

18 Principles of Management of Patients With Cancer, 265

Paul Symonds and Angela Duxbury

- Introduction, 265
- Factors Governing Clinical Decisions, 266
 - Tumour Factors, 266
 - Patient Factors, 267
 - Treatment Modality, 267
 - Support Services, 269
 - Palliative Care, 270

Pain Control, 270
 Nausea and Vomiting, 271
 Context of Care, 271
 Further Reading, 271

19 Chemotherapy and Hormones, 272

Anne L. Thomas

Introduction, 272

General Indications for Chemotherapy, 272
 Development and Testing of Anticancer Agents, 272
 Phase I Studies, 273
 Phase II Studies, 273
 Phase III Studies, 273
 Assessing Tumour Responses, 273
 The Evaluation of Targeted Therapies, 273

Principles of Cytotoxic Therapy, 273

Drug Resistance, 274
 Selection and Scheduling of Chemotherapy Agents, 274

High-Dose Chemotherapy, 274

Route of Administration, 274

Side Effects of Chemotherapy, 275

Classification of Cytotoxic Drugs, 275

Alkylating Agents, 275
 Antimetabolites, 275
 Mitotic Inhibitors, 278
 Topoisomerase Inhibitors, 279
 Miscellaneous, 279
 Hormones, 280
 Targeted Therapies, 281
 Epidermal Growth Factor Receptor, 282
 Signalling Through RAS-RAF-ERK (MAPK) and PI3K-AKT, 282
 Vascular Endothelial Growth Factor Signalling Pathway, 282
 Proteasome Inhibitors, 282
 Poly(ADP-Ribose) Polymerase Inhibitors, 282
 CDK4/6 Inhibitors, 283
 Immunotherapy, 283
 Therapeutic Antibodies, 283
 Immune Checkpoint Inhibitors, 283

Further Reading, 284

20 Skin and Lip Cancer, 285

Charles Kelly and Paul Symonds and
 Cliff Lawrence

Introduction, 285

Keratinocyte Skin Tumours, 285

Aetiology, 285
 Basal Cell Carcinoma, 287
 Squamous Cell Carcinoma of the Skin, 289
 Cancer of the Lip, 289
 Keratoacanthoma, 289
 Treatment of Nonmelanoma Skin Cancer, 290
 Radiotherapy for Keratinocyte Skin Cancers, 292
 Electron Beam Treatment, 293
 Electron Backscatter, 293
 Superficial X-Ray Treatment, 293

Comparison of Outcome for Different Modalities in the Treatment of Basal Cell Carcinomas, 296

Melanoma, 296

Aetiology, 296
 Subtypes of Melanoma, 296
 Diagnosis, 297
 Melanoma TNM Staging, 297
 Stage and Prognosis, 297
 Management of Melanoma, 300
 Adjuvant Treatment for Melanoma, 301
 Management of Recurrent or Metastatic Melanoma, 301
 Side Effects of Immunotherapy, 302
 Role of Radiotherapy in Malignant Melanoma, 302
 Cutaneous Lymphomas, 303
 Merkel Cell Tumours, 303
 Skin Sarcoma, 303
 Kaposi Sarcoma, 305
 Skin Appendage Tumours, 305
 Further Reading, 306

21 Head and Neck Cancer—General Principles, 308

Christopher D. Scrase

Introduction, 308

Demographics, 308

Aetiology, 308

Prevention and Early Diagnosis, 310

Tumour Types, 310

Presentation, 310

Investigation, 310

Nutrition, 311

Dentition, 311

Indications for Radiotherapy, 311

Definitive Radiotherapy, 311

Postoperative Radiotherapy, 311

Palliative Radiotherapy, 311

Radiotherapy Planning, 312

Immobilisation, 312

Target Volumes, 312

Definitive Radiotherapy, 312

Postoperative Radiotherapy, 313

Radiotherapy Technique, 313

Conformal Radiotherapy, 313

Intensity Modulated and Image Guided

Radiotherapy in Head and Neck Cancers, 313

Dose and Fractionation, 317

Definitive Radiotherapy, 317

Postoperative Radiotherapy, 318

Chemotherapy in Head and Neck Cancer, 318

Concurrent Chemotherapy and Definitive Radiotherapy, 318

Concurrent Chemotherapy and Postoperative Radiotherapy, 318

Induction Chemotherapy, 318

Chemotherapy in the Palliative Setting, 318

Toxicity of Treatment, 319

Acute Toxicity, 319

- Late Toxicity*, 320
- Future Developments*, 320
- Immunotherapy*, 320
- Further Reading*, 320

22 Sino-Nasal, Oral, Larynx and Pharynx Cancers, 322

Christopher D. Scrase and Paul Symonds

Nasopharynx, 323

- Anatomy*, 323
- Incidence of Nasopharyngeal Tumours*, 323
- Staging System for Nasopharyngeal Tumours*, 324
- Aetiology, Pathology and Lymphatic Spread*, 324
- Signs and Symptoms*, 324
- Diagnosis and Staging*, 324
- Treatment*, 324
- Radiation Technique*, 325
- Complications*, 325
- Follow-up*, 325
- Results*, 326

Nose and Nasal Cavity, 326

- Anatomy*, 326
- Incidence*, 328
- Staging System*, 328
- Aetiology, Pathology and Lymphatic Spread*, 328
- Signs and Symptoms*, 328
- Diagnosis and Staging*, 328
- Treatment*, 328
- Complications*, 330
- Results*, 330

Paranasal Sinus Tumours, 330

- Anatomy*, 330
- Incidence of Paranasal Sinus Tumours*, 330
- Staging System for Paranasal Sinus Tumours*, 330
- Aetiology, Pathology and Lymphatic Spread*, 331
- Signs and Symptoms*, 331
- Diagnosis and Staging*, 332
- Treatment*, 332
- Complications*, 332
- Follow-up*, 333
- Results*, 333

Lip and Oral Cavity Carcinoma, 333

- Anatomy*, 333
- Incidence of Oral Cavity Carcinoma*, 333
- Staging System for Oral Cavity and Lip Carcinoma (TNM, 8th Edition)*, 333
- Aetiology, Pathology and Lymphatic Spread*, 334
- Signs and Symptoms*, 334
- Diagnosis and Staging*, 335
- Treatment Lip Cancers*, 336
- Radiotherapy Technique*, 337
- Radiotherapy Technique*, 338
- Follow-up*, 338
- Results of Treatment*, 338

Oropharyngeal Carcinoma, 338

- Anatomy*, 338
- Staging System of Oropharyngeal Tumours*, 339
- Aetiology, Pathology and Lymphatic Spread*, 339

- Signs and Symptoms*, 339
- Diagnosis and Staging*, 340
- Treatment*, 340
- Radiation Technique*, 340
- Complications*, 342
- Follow-up*, 342
- Results*, 342

Larynx, 342

- Anatomy*, 342
- Incidence of Laryngeal Cancer*, 343
- Staging System for Laryngeal Cancer (TNM, 8th Edition)*, 343
- Aetiology, Pathology and Lymphatic Spread*, 344
- Signs and Symptoms*, 344
- Diagnosis and Staging*, 344
- Treatment*, 345

Glottic Cancers, 345

- Complications of Treatment for Early Laryngeal Cancer*, 345
- Results of Treatment*, 348

Hypopharyngeal Carcinoma, 348

- Anatomy*, 348
- Incidence of Hypopharyngeal Tumours*, 348
- Staging System of Hypopharyngeal Tumours (TNM, 8th Edition)*, 348
- Aetiology, Pathology and Lymphatic Spread*, 348
- Signs and Symptoms*, 348
- Diagnosis and Staging*, 348
- Treatment*, 348
- Radiotherapy Technique*, 348
- Complications*, 351
- Follow-up*, 351
- Results*, 352

Further Reading, 352

23 Thyroid Cancer, 353

Charles Kelly and Paul Symonds

Introduction and Epidemiology, 353

- Anatomy*, 353
- Aetiological Factors*, 353
- Presentation, Diagnosis and Patient Pathway*, 354
- Differentiated Thyroid Cancer, 355*
 - Management of Differentiated Thyroid Cancer*, 356
 - Surgery*, 356
 - Radioiodine Ablation*, 357
 - Thyroglobulin*, 358
 - Management of Hypocalcaemia*, 358
 - Management of Locoregional Recurrence*, 358
 - Metastatic Disease*, 358
- Medullary Thyroid Cancer*, 358
- Anaplastic Thyroid Cancer*, 359
- Thyroid Lymphoma*, 359
- Thyroid Sarcoma*, 359
- Hurthle Cell Carcinoma*, 359
- External Beam Radiotherapy for Thyroid Cancer*, 359

- As Adjuvant Treatment, 359
- Palliative High Dose, 360
- Low Dose Palliation, 360
- Radiotherapy for Thyroid Lymphoma, 362
- Follow-Up Policy for Thyroid Cancer Patients, 363
- Further Reading, 363

24 Gastrointestinal Cancer, 364

Somnath Mukherjee and Maria Hawkins

- Cancer of the Oesophagus, 364**
 - Epidemiology, 364
 - Aetiology and Pathology, 365
 - Risk Factors for Squamous Cell Carcinomas, 365
 - Risk Factors for Adenocarcinoma, 365
 - Anatomy, 365
 - Clinical Manifestations, 365
 - Diagnostic Evaluation, 365
 - Therapy, 366
 - Radical Radiotherapy, 366
 - Definitive Chemoradiation, 366
 - Neoadjuvant Chemoradiation, 366
 - Adjuvant Radiation or Chemoradiation, 367
 - Palliative Radiotherapy, 367
 - Radiation Therapy Techniques, 367
 - Chemotherapy, 369
 - Other Treatments, 369
 - Oesophagogastric Junctional Tumours, 369
 - Summary, 369
- Cancer of the Stomach, 369**
 - Anatomy, 369
 - Epidemiology, 369
 - Aetiology, 369
 - Pathology, 369
 - Clinical Features, 370
 - Staging, 370
 - Management, 370
 - Radiation Techniques, 371
 - Palliative Treatments in Advanced/Metastatic Gastric Cancer, 371
 - Summary, 371
- Pancreas, 371**
 - Anatomy, 371
 - Incidence and Epidemiology, 372
 - Pathology, 372
 - Diagnostic Evaluation and Imaging, 372
 - Therapy, 372
- Hepatocellular Carcinoma, 375**
 - Epidemiology, 375
 - Symptomatology, 375
 - Diagnostics and Classification, 375
 - General Management Principles, 375
 - Surgical Therapy, 375
 - Liver Transplantation, 375
 - Locoregional Treatments, 375
 - Systemic Therapy and Molecularly Targeted Agents, 376

- Radiation Therapy, 376**
 - Principles of Radiation Delivery, 376
- Future Perspectives, 377**
 - Biliary Tract Cancers, 378
 - Principles of Radiotherapy, 378
- Cancer of the Colon and Rectum, 378**
 - Epidemiology, 378
 - Aetiology, 378
 - Histopathology and Clinical Features, 379
 - Pretreatment Staging Evaluations, 379
 - Staging Systems, 379
 - Colon Cancer—Treatment Principles, 380
 - Management of Advanced Colorectal Cancer, 380
 - Third-Line Options, 380
 - Rectal Cancer—Treatment Principles, 381
 - Organs at Risk, 381
- Anal Cancer, 382**
 - Epidemiology and Aetiology, 382
 - Anatomy, 382
 - Histopathology, 382
 - Clinical Features, 382
 - Treatment, 383
- References (Oesophagogastric), 386**
- References (Pancreas), 386**
- References (hepato-biliary, colo-rectal and anal cancer), 386**

25 Tumours of the Thorax, 388

Michael Snee

- Lung Cancer, 388**
 - Pathology, 388
 - Symptoms, 388
 - Diagnosis and Staging, 389
 - Systemic Treatment for Nonsmall Cell Lung Cancer, 394
 - Chemotherapy, 394
 - Targeted Therapy, 395
 - Immune Therapy, 395
 - Small Cell Lung Cancer, 395
 - Neuroendocrine Tumours, 396
 - Mesothelioma, 396
 - Symptoms, 397
 - Diagnosis, 397
 - Pathology and Natural History, 397
 - Management, 397
 - Conclusion, 398**
 - Further Reading, 398**
- ## 26 Breast Cancer, 399
- Ian Kunkler*
- Anatomy, 400**
 - Lymphatic Drainage, 400
 - Pathology, 400**
 - Epidemiology, 400
 - Aetiology, 400
 - Ductal and Lobular Carcinoma In Situ, 402
 - Invasive Breast Cancer, 402

- Molecular Classification of Breast Cancer, 402
 - Multidisciplinary Management of Breast Cancer, 402
 - Diagnosis, 403
 - Clinical Assessment, 403
 - Breast Ultrasound, 403
 - Magnetic Resonance Imaging, 404
 - Positron Emission Tomography, 404
 - Obtaining a Histological Diagnosis, 404
 - Staging, 404
 - Staging Investigations, 405
 - Management of Ductal Carcinoma In Situ, 406
 - Role of Postoperative Radiotherapy for Ductal Carcinoma In Situ, 407
 - Prognostic and Predictive Factors for Invasive Breast Cancer, 408
 - Stage, 408
 - Age, 408
 - Tumour Size, 408
 - Axillary Node Status, 408
 - HER2/neu Status, 409
 - Lymphovascular Invasion, 409
 - Prognostic Indices, 409
 - Hormonal Receptor Status, 409
 - Ki67, 409
 - Molecular Subtype, 409
 - Gene Profiling, 409
 - Endocrine Therapy, 409
 - Mastectomy or Breast Conservation, 410
 - Management of the Axilla, 411
 - Regional Nodal Irradiation, 411
 - Indications for Internal Mammary Irradiation, 413
 - Postoperative Radiotherapy, 413
 - Target Volume and Techniques for Locoregional Irradiation, 416
 - Computed Tomography Simulation, 416
 - Intensity Modulated Radiotherapy, 416
 - Shoulder Field, 417
 - Neoadjuvant Therapy, 417
 - Adjuvant Hormonal and Cytotoxic Therapy, 425
 - Rationale, 425
 - Who Benefits?, 426
 - Adjuvant Endocrine Therapy, 426
 - Adjuvant Tamoxifen, 427
 - Aromatase Inhibitors, 427
 - Adjuvant Hormonal Therapy After 5 Years of Tamoxifen, 428
 - Toxicity of Tamoxifen, 429
 - Tamoxifen Plus Chemotherapy, 429
 - Adjuvant Ovarian Suppression, 429
 - Adjuvant/Neoadjuvant Combination Chemotherapy (Polychemotherapy), 429
 - Neoadjuvant Chemotherapy, 429
 - Postoperative Adjuvant Chemotherapy, 430
 - HER2 Positive Breast Cancer, 430
 - Triple Negative Breast Cancer, 434
 - Adjuvant Chemotherapy in Older Patients, 434
 - Management of Locally Advanced Breast Cancer, 434
 - Clinical Features, 434
 - Diagnosis, 434
 - Principles of Management, 434
 - Role of Surgery, 434
 - Choice of Systemic Therapy, 434
 - Hormonal Therapy, 435
 - Locoregional Therapy, 435
 - Target Volume, 435
 - Technique, 435
 - Dosage and Fractionation (Radical), 435
 - Locoregional Palliative Radiotherapy, 435
 - Technique, 435
 - Dose, 435
 - Bone Metastases: Prevention and Treatment, 435
 - Palliative Radiotherapy for Bone Metastases, 436
 - Palliative Surgery, 436
 - Principles of Management, 436
 - Medical Management of Advanced and Metastatic Disease, 436
 - Menopausal Status and Hormone Receptor Status, 436
 - Sites of Metastases and Impact on Management, 437
 - Cytotoxic Therapy, 437
 - Morbidity of Chemotherapy (Adjuvant and for Metastatic Disease), 440
 - Bone Marrow Involvement, 440
 - Growth Factor Support, 441
 - Clinical Outcomes in Early and Advanced Metastatic Breast Cancer, 441
 - Follow-Up, 441
 - Follow-Up After Breast-Conserving Therapy, 442
 - Follow-Up After Mastectomy, 442
 - Breast Cancer in Pregnancy, 442
 - Breast Cancer in Males, 443
 - Further Reading, 443
- 27 Gynaecological Cancer, 444**
 Christopher Kent and Paul Symonds
- Anatomy, 444
 - Incidence of Gynaecological Cancer, 444
 - Carcinoma of Cervix, 444
 - Causes of Cervical Neoplasia, 444
 - Pathology of Cervical Cancer, 444
 - Symptoms and Investigations of Cervical Cancer, 445
 - Treatment, 448
 - Treatment of Stage II–IVa, 449
 - Future Trends, 451
 - Carcinoma of Endometrium, 452
 - Pathology, 453
 - Routes of Spread, 453
 - Treatment, 453
 - Postoperative Radiotherapy, 453
 - Future Trends, 454
 - Sarcomas of the Uterus, 454
 - Cancer of the Ovary, 454
 - Aetiology, 454

- Pathology, 454
 - Method of Spread, 454
 - Clinical Features, 454
 - Investigations and Staging, 454
 - Treatment, 455
 - Chemotherapy, 455
 - Radiotherapy, 455
 - Future Trends, 456
 - Rare Tumours of the Ovary, 456
 - Sex-Cord Tumours, 456
 - Germ-Cell Tumours, 456
 - Tumours of the Vagina and Vulva, 456
 - Further Reading, 457
- 28 Cancer of Kidney, Bladder, Prostate, Testis, Urethra and Penis, 458**
Aravindhan Sundaramurthy and Duncan B. McLaren
- Kidney, 458
 - Anatomy, 458
 - Pathology, 458
 - Clinical Features, 459
 - Investigation and Staging, 459
 - Treatment, 460
 - Results of Treatment, 461
 - Bladder, 461
 - Anatomy, 461
 - Pathology, 461
 - Aetiology, 461
 - Epidemiology, 461
 - Macroscopic Appearance, 461
 - Microscopic Appearance, 461
 - Clinical Features, 462
 - Investigation and Staging, 462
 - Treatment, 462
 - Results of Treatment, 465
 - Prostate, 465
 - Anatomy, 465
 - Pathology, 465
 - Hormonal Sensitivity, 466
 - Prostate-Specific Antigen and Screening, 466
 - Clinical Features, 466
 - Diagnosis and Staging, 466
 - Treatment, 467
 - Testis, 471
 - Anatomy, 471
 - Pathology, 472
 - Tumour Markers, 472
 - Clinical Features, 472
 - Diagnosis and Staging, 473
 - Treatment, 474
 - Testicular Lymphoma, 476
 - Dose and Energy, 476
 - Results of Treatment, 476
 - Urethra, 476
 - Female Urethra, 476
 - Treatment, 476
 - Results of Treatment, 476

- Penis, 476
 - Pathology, 476
 - Clinical Features, 476
 - Staging, 476
 - Treatment, 477
 - Results of Treatment, 478
- Further Reading, 478

29 Lymphoma and Disease of Bone Marrow, 479

Matthew Ahearn and Lesley Speed

- Introduction, 479
 - Aetiology and Epidemiology, 479
 - Pathological Characteristics, 480
 - Clinical Features, 481
 - Diagnosis and Staging, 481
 - Clinical Prognostic Factors, 481
 - Treatment, 481
- Multiple Myeloma, 483
 - Pathology, 483
 - Clinical Features, 483
 - Diagnosis, 484
 - Prognostic Factors, 484
 - Treatment, 484
- Leukaemia, 484
 - Acute Leukaemia, 484
 - Chronic Myeloid Leukaemia, 485
 - Chronic Lymphocytic Leukaemia, 485
- Myeloproliferative Disorders, 485
- Haemopoietic Stem Cell Transplantation, 486
- Radiotherapy Doses, Techniques and Toxicities, 486
 - Hodgkin's Lymphoma, 486
 - Non-Hodgkin's Lymphoma, 486
 - Treatment Techniques, 487
 - Extra-Nodal Sites, 487
 - Leukaemia, 491
 - Myeloma, 491
 - Mycosis Fungoides, 492
- Chemotherapy Regimens and Toxicities, 492
 - Hodgkin's Lymphoma, 493
 - Non-Hodgkin's Lymphoma, 493
 - Mantle Cell, 493
 - Diffuse Large B Cell, T-Cell-Rich, B Cell, Follicular Grade 3b (and for T-Cell Lymphomas), 493
 - Myeloma, 493
 - Acute Myeloid Leukaemia, 494
- Further Reading, 494

30 Tumours of the Central Nervous System, 495

Pinelopi Gkogkou, Sarah J. Jefferies, and Neil G. Burnet

- Introduction, 496
- Tumour Types, 496
- Anatomy of the Central Nervous System, 496
 - Anatomy of the Brain, 496
 - Anatomy of the Cerebrospinal Fluid Pathways and Hydrocephalus, 497
 - Anatomy of the Skull and Meninges, 498

Clinical Features—Presentation of Brain Tumours, 499
Specific Focal Neurological Deficit, 499
Epileptic Seizure, 499
Raised Intracranial Pressure, 499
Nonspecific Symptoms, 499
Principles of Management, 499
Diagnosis—A Combination of History, Imaging and Pathology, 499
Performance Status in the Treatment Decision, 499
Principles of Neurosurgery, 499
Principles of Radiotherapy Planning for Central Nervous System Tumours, 500
Planning Volumes, 501
Normal Tissue Tolerance to Radiotherapy, 501
Principles of Steroid Therapy, 502
Principles of Additional Supportive Care, 502
Driving After a Diagnosis of Central Nervous System Tumour, 502
Individual Tumour Types, 502
High-Grade Gliomas, 502
Pathology and Clinical Features, 502
Treatment, 503
Radical Treatment, 504
Palliative Treatment, 505
Elderly Patients, 505
Low-Grade Gliomas, 506
Pathology and Clinical Features, 506
Radical Treatment, 507
Ependymoma (Intracranial), 507
Pathology and Clinical Features, 507
Treatment, 508
Central Nervous System Lymphoma, 508
Pathology and Clinical Features, 508
Management Principles, 509
Radical Treatment—Full Dose Radiotherapy, 509
Localised Unifocal Disease, 509
Palliative Radiotherapy, 509
Elderly Population, 509
Germinoma, 509
Clinical Features and Management Principles, 509
Treatment, 510
Medulloblastoma, 510
Meningioma, 510
Pathology and Clinical Features, 510
Treatment, 510
Pituitary Tumours and Craniopharyngioma, 512
Pituitary Tumours, 512
Pathology and Clinical Features, 512
Treatment, 512
Craniopharyngioma, 513
Pathology and Clinical Features, 513
Treatment, 513
Vestibular Schwannoma, 514
Pathology and Clinical Features, 514
Treatment, 515
Chordomas and Low-Grade Chordosarcomas, 516
Pathology and Clinical Features, 516

Treatment, 516
Spinal Cord Tumours—Primary, 517
Pathology and Clinical Features, 517
Treatment—Radical, 517
Treatment—Palliative, 517
Cerebral Metastases, 518
Clinical Features and Management Principles, 518
Patients With Multiple Brain Metastasis, 518
Patients With One to Three Brain Metastasis, 518
Treatment, 519
Hypofractionated Radiotherapy, 519
Stereotactic Radiosurgery, 519
Spinal Cord Compression, 519
Pathology and Clinical Features, 519
Management Principles, 519
Steroids, 520
Surgery and Radiotherapy, 520
External Beam Radiotherapy, 520
Stereotactic Body Radiation Therapy, 520
Further Reading, 520

31 Eye and Orbit, 524

Tom Roques and Adrian Harnett

Anatomy, 524
Principles of Radiotherapy to the Eye, 524
Radiation and Ocular Morbidity, 525
The Lens, 525
The Sclera and Retina, 525
The Cornea and Lacrimal Apparatus, 525
The Optic Nerves and Chiasm, 526
Benign Conditions, 526
Thyroid Eye Disease, 526
Orbital Pseudotumour, 527
Malignant Tumours, 527
Primary Malignant Tumours, 527
Skin Cancers Involving the Eyelid, 527
Lacrimal Gland and Nasolacrimal Duct Cancer, 528
Tumours Arising From Adjacent Structures, 528
Lymphoma, 528
Ocular Melanoma, 529
Retinoblastoma, 530
Metastases, 531
Further Reading, 531

32 Sarcomas, 532

Thankamma V. Ajithkumar

Soft Tissue Sarcomas, 532
Pathology, 532
Clinical Features, 533
Diagnosis and Staging, 533
Management, 535
Chemotherapy, 536
Retroperitoneal Sarcomas, 536
Radiotherapy Technique, 537
Radiotherapy Side Effects, 538
Proton Therapy, 538
Results of Treatment, 539

Bone Tumours, 539*Osteosarcoma (Osteogenic Sarcoma), 539**Pathology, 539**Clinical Features, 539**Diagnosis and Staging Investigations, 540**Treatment, 540**Results of Treatment, 541**Ewing Sarcoma, 541**Pathology, 541**Clinical Features, 541**Diagnosis and Staging, 541**Treatment, 541**Radiotherapy Side Effects, 543**Results of Treatment, 543***Chondrosarcoma, 543***Clinical Features, 543**Diagnosis and Investigation, 543**Treatment, 543**Radiotherapy, 543**Chemotherapy, 543**Results of Treatment, 543***Undifferentiated Pleomorphic Sarcoma of Bone, 543***Secondary Tumours in Bone, 544**Clinical Features and Investigation, 544**Treatment, 544**Pathological Fracture, 545***Further Reading, 545****33 Principles of Paediatric Oncology, 546***Roger E. Taylor***Introduction, 546****Toxicity of Radiotherapy for Children, 547***Acute Morbidity, 547**Subacute Effects, 547**Long-Term Effects, 547***Tolerance of Critical Organs to Radiotherapy, 548****Chemotherapy/Radiotherapy Interactions, 548****Radiotherapy Quality Assurance, 548****Leukaemia, 548***Total Body Irradiation, 549***Hodgkin Lymphoma, 550****Non-Hodgkin Lymphoma, 550****Neuroblastoma, 550***Metaiodobenzylguanidine Therapy for**Neuroblastoma, 551***Wilms Tumour (Nephroblastoma), 551****Rhabdomyosarcoma, 551****Ewing Sarcoma/Peripheral Primitive***Neuroectodermal Tumour, 554***Osteosarcoma, 554****Central Nervous System Tumours, 555***Long-Term Effects of Radiotherapy for Central**Nervous System Tumours, 555**Chemotherapy for Central Nervous System**Tumours, 555**Low-Grade Astrocytoma, 555**High-Grade Astrocytoma, 557**Brainstem Glioma, 557**Ependymoma, 558**Embryonal Tumours, 558**Intracranial Germ Cell Tumours, 559**Craniopharyngioma, 564**Proton Therapy for Paediatric Tumours, 565***Conclusions, 565****Further Reading, 565****34 Care of Patients During Radiotherapy, 566***Lorraine Webster and Angela Duxbury***Introduction, 566****Assessment of Individual Patient and Carer Needs, 566****Skin Reactions, 567****Nutrition, 568****Nausea, Vomiting and Diarrhoea, 569****Fatigue, 569****Psychosocial Issues, 569****Communication, 570****Information, 571****Consent, 572****Spiritual Needs, 572****Complementary Therapies, 572****The Impact on Staff, 573****Further Reading, 573****35 Medical Complications of Malignant Disease, 575***Robert Coleman and Harriet S. Walter***Effusions Secondary to Malignant Disease, 575***Pleural Effusions, 575**Pericardial Effusions, 576**Peritoneal Effusions (Ascites), 576**Venous Thrombosis, 576***Metabolic and Endocrine Manifestations of****Malignancy, 577***Hypercalcaemia, 577**Inappropriate Secretion of Antidiuretic Hormone, 577**Other Endocrine Manifestations of Malignancy, 577**Hyperuricaemia and Tumour Lysis Syndrome, 577***Infection, 577****Paraneoplastic Syndromes, 578***Neurological, 578**Hypertrophic Pulmonary Osteoarthropathy, 578**Other Paraneoplastic Syndromes, 578***Further Reading, 578****36 Proton Beam Therapy, 579***Jenny Gains, Laura Beaton, Richard A. Amos, and Ricky A. Sharma***Introduction, 579****Physics and Technology of Proton Beam Therapy, 579***Physical Characteristics of Proton Beams, 579**Proton Therapy Systems Overview, 580**Passively Scattered Proton Beams, 580**Active Proton Pencil Beam Scanning, 581**Sources of Physical and Biological Uncertainties, 581**Treatment Planning and Delivery, 582***Proton Beam Therapy in Children, Teenagers and Young Adults, 582***Low-Grade Astrocytoma, 583*

| | |
|--|---|
| <i>Ependymoma</i> , 583 | <i>Central Nervous System Tumours</i> , 586 |
| <i>Medulloblastoma</i> , 583 | <i>Intraocular Melanoma</i> , 586 |
| <i>Craniopharyngioma</i> , 583 | <i>Gastrointestinal Malignancies</i> , 586 |
| <i>Retinoblastoma</i> , 583 | <i>Prostate Cancer</i> , 586 |
| <i>Rhabdomyosarcoma</i> , 584 | <i>Lung Cancer</i> , 586 |
| <i>Ewing Sarcoma</i> , 584 | <i>Other Cancers and Role of Proton Beam Therapy in</i> |
| <i>Other Paediatric Tumours</i> , 584 | <i>Retreatment</i> , 586 |
| Proton Beam Therapy for Adult Cancers , 584 | Conclusions and Future Directions , 586 |
| <i>Chordoma and Chondrosarcomas</i> , 585 | Further Reading , 587 |
| <i>Paraspinal Tumours and Sarcomas</i> , 585 | |
| <i>Nasal Cavity and Paranasal Sinuses</i> , 586 | Index , 589 |